A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

SELUTION SLR Sirolimus Drug Eluting Balloon for Endovascular Applications Receives CE Approval: Award Supported by 2 Year Results from the SELUTION SLR First-in-Human Study Involving 50 Patients

SELUTION SLR Sirolimus Drug Eluting Balloon (DEB), for the treatment of peripheral arterial disease has received the CE Mark. This approval applies to sizes from 2.0 x 20mm to 7.0 x 150mm.

This award was supported by two-year results from the SELUTION SLR First-in-Human study, involving 50 patients enrolled across four German centres. SELUTION SLR is the first and only sirolimus drug eluting balloon to have 6 months’ clinical follow-up demonstrating a 2.3% Target Lesion Revascularization (TLR) and a 0.19 Late Lumen Loss (LLL). Two-year clinical results confirmed no deaths or amputations. Patients demonstrated clinical improvement as measured by Rutherford Classification, ABI and walking distance at 6 months and one year, which was maintained out to two years. This evidence demonstrates that a sustained limus release drug eluting balloon is both safe and effective for the treatment of femoropopliteal lesions over a prolonged period.

The study involved 50 patients enrolled across four German centres and achieved excellent freedom from TLR through to two years in 87.5% of subjects, with no primary TLR event observed after Month 11. These figures are low compared to reported historical First-in-Human studies. There were no incidences of death or the need for minor and/or major amputations over this period. These Patients demonstrated clinical improvement as measured by Rutherford Classification, ABI and walking distance at six months and one year, which was maintained out to two years.

“We are very excited to have been awarded our first CE Mark, which is testament to the documented efficacy and safety of our novel sustained limus release eluting balloon”, said MedAlliance Chairman and CEO Jeffrey B. Jump. “We now anticipate that patients in all markets where the CE Mark is recognized will be able to benefit from this breakthrough in drug eluting technology.”

MedAlliance has recently announced completion of its Below The Knee (BTK) First-in-Human study in Singapore. Studies in Arterial Venus Fistula (AVF) and Pedal Arch are to start enrolling soon. A 500 patient post marketing clinical study will follow shortly.

SELUTION SLR Sirolimus Drug Eluting Balloon technology involves unique Micro-Reservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These micro-reservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been demonstrated highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the micro-reservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy